Search

Your search keyword '"Marzo T"' showing total 107 results

Search Constraints

Start Over You searched for: Author "Marzo T" Remove constraint Author: "Marzo T"
107 results on '"Marzo T"'

Search Results

3. Elective cancer surgery in COVID-19–Free surgical pathways during the SARS-cov-2 pandemic: An international, multicenter, comparative cohort study

6. The combined activation of K Ca 3.1 and inhibition of K v 11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

7. The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

9. Rational drug design paradigms: the odyssey for designing better drugs

11. PtI2(DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features.

12. The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct

13. Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells

14. Arsenoplatin-1 Is a Dual Pharmacophore Anticancer Agent

15. Synthesis, DNA binding studies, and antiproliferative activity of novel Pt(II)-complexes with an L-alanyl-based ligand

16. The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells

17. Oxaliplatin vs. cisplatin: competition experiments on their binding to lysozyme

18. Peculiar Features in the Crystal Structure of the Adduct Formed between cis-PtI2(NH3)2 and Hen Egg White Lysozyme

19. Detailed mechanism of a DNA/RNA nucleobase substituting bridging ligand in diruthenium(II,III) and dirhodium(II,II) tetraacetato paddlewheel complexes: protonation of the leaving acetate is crucial.

20. Dimolybdenum (II,II) paddlewheel complexes bearing non-steroidal anti-inflammatory drug ligands: Insights into the chemico-physical profile and first biological assessment.

21. Non-Medical Applications of Inorganic Medicines. A Switch Based on Mechanistic Knowledge.

22. Description of a Non-Canonical AsPt Blue Species Originating from the Aerobic Oxidation of AP-1 in Aqueous Solution.

23. Unveiling the mechanism of activation of the Te(IV) prodrug AS101. New chemical insights towards a better understanding of its medicinal properties.

24. Tyrosine kinase inhibitors (TKIs) for ovarian cancer treatment: from organic to inorganic chemotherapeutics towards selectivity-a perspective overview.

25. Oxaliplatin(IV) Prodrugs Functionalized with Gemcitabine and Capecitabine Induce Blockage of Colorectal Cancer Cell Growth-An Investigation of the Activation Mechanism and Their Nanoformulation.

26. A complex bearing TSPO PIGA ligand coordinated to the [Au(PEt 3 )] + pharmacophore is highly cytotoxic against ovarian cancer cells.

27. An unprecedented palladium-arsenic catalytic cycle for nitriles hydration.

28. Cisplatin binding to angiogenin protein: new molecular pathways and targets for the drug's anticancer activity.

29. Mechanistic Evaluations of the Effects of Auranofin Triethylphosphine Replacement with a Trimethylphosphite Moiety.

30. Inorganic Drugs as a Tool for Protein Structure Solving and Studies on Conformational Changes.

31. Pd-Based Hybrid Nanoparticles As Multimodal Theranostic Nanomedicine.

32. Neurotrophic Activity and Its Modulation by Zinc Ion of a Dimeric Peptide Mimicking the Brain-Derived Neurotrophic Factor N-Terminal Region.

33. Medicinal Hypervalent Tellurium Prodrugs Bearing Different Ligands: A Comparative Study of the Chemical Profiles of AS101 and Its Halido Replaced Analogues.

34. Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation.

35. Reactions of Arsenoplatin-1 with Protein Targets: A Combined Experimental and Theoretical Study.

36. Auranofin and its analogs as prospective agents for the treatment of colorectal cancer.

37. Cancer Immunotherapy: An Overview of Small Molecules as Inhibitors of the Immune Checkpoint PD-1/PD-L1 (2015-2021).

38. Oxaliplatin inhibits angiogenin proliferative and cell migration effects in prostate cancer cells.

39. In Vitro Anti-SARS-CoV-2 Activity of Selected Metal Compounds and Potential Molecular Basis for Their Actions Based on Computational Study.

40. Agricultural expansion and the ecological marginalization of forest-dependent people.

41. Angiogenin and Copper Crossing in Wound Healing.

42. Reactivity of antitumor coinage metal-based N-heterocyclic carbene complexes with cysteine and selenocysteine protein sites.

43. Peptides Derived from Angiogenin Regulate Cellular Copper Uptake.

44. Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA-PEG nanoparticles.

45. Two mixed valence diruthenium(II,III) isomeric complexes show different anticancer properties.

46. Strategies for the Improvement of Metal-Based Chemotherapeutic Treatments.

47. Ruthenium(II) 1,4,7-trithiacyclononane complexes of curcumin and bisdemethoxycurcumin: Synthesis, characterization, and biological activity.

49. The first step of arsenoplatin-1 aggregation in solution unveiled by solving the crystal structure of its protein adduct.

50. The Effects on Angiogenesis of Relevant Inorganic Chemotherapeutics.

Catalog

Books, media, physical & digital resources